Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
211At-AmbiTag
- Development stage
- Preclinical
- Lead developer
- TetraKit Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
211At-AmbiTag (also known as 211At-AstraTate) is an investigational, SSTR-targeted alpha-particle radioligand therapy being developed by TetraKit Technologies in collaboration with Atley Solutions. The therapeutic candidate consists of a somatostatin receptor (SSTR) antagonist conjugated to the alpha-emitting radionuclide astatine-211 (211At) using TetraKit's proprietary radiolabeling platform. By targeting SSTR, which is highly expressed on neuroendocrine tumors (NETs), 211At-AmbiTag selectively delivers high-energy alpha radiation directly to cancer cells, inducing lethal DNA double-strand breaks while minimizing damage to surrounding healthy tissues. The drug is currently in the discovery and preclinical stage of development for the treatment of neuroendocrine tumors.
- Other names
- 211At-AstraTateAstraTate
02
Targets
DNASSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 211At-AmbiTag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 211At-AmbiTag.